MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

Search

Emergent BioSolutions Inc

Atvērts

SektorsVeselības aprūpe

4.46 -0.67

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.12

Max

4.7

Galvenie mērījumi

By Trading Economics

Ienākumi

-146M

-31M

Pārdošana

-105M

189M

EPS

-0.578

Peļņas marža

-16.535

Darbinieki

900

EBITDA

-164M

13M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+231.86% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 30. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

420M

540M

Iepriekšējā atvēršanas cena

5.13

Iepriekšējā slēgšanas cena

4.46

Ziņu noskaņojums

By Acuity

50%

50%

133 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Emergent BioSolutions Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. apr. 22:38 UTC

Karstas akcijas

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

2025. g. 7. apr. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Woodside Energy: Stonepeak's Total Contribution Lower Than Nominal Equity Interest Give Accelerated Spend

2025. g. 6. apr. 23:58 UTC

Iegādes, apvienošanās, pārņemšana

Woodside Energy: Deal 'a Material Step' Toward Readiness for Final Investment Decision

2025. g. 6. apr. 23:58 UTC

Iegādes, apvienošanās, pārņemšana

Woodside Energy: Deal 'Significantly Reduces' Company's Capex Profile

2025. g. 6. apr. 23:57 UTC

Iegādes, apvienošanās, pārņemšana

Woodside Energy: Stonepeak to Contribute 75% of Project Capex in Both 2025, 2026

2025. g. 6. apr. 23:57 UTC

Iegādes, apvienošanās, pārņemšana

Woodside Energy: Stonepeak to Provide $5.7 Billion Towards Expected Project Capex

2025. g. 6. apr. 23:57 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. apr. 23:57 UTC

Tirgus saruna

Nervous Start For AUD/USD; Watch on CNY Fix -- Market Talk

2025. g. 6. apr. 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Woodside Energy: Signs Deal With Stonepeak for Sale of 40% Interest in Louisiana LNG Infrastructure

2025. g. 6. apr. 23:52 UTC

Tirgus saruna

Gold Slips; Likely Unwinding of Long Positions to Raise Cash -- Market Talk

2025. g. 6. apr. 23:39 UTC

Tirgus saruna

Oil Futures Slide on Fears of Weakening Global Demand -- Market Talk

2025. g. 6. apr. 23:39 UTC

Tirgus saruna

Nikkei May Fall as U.S. Tariffs Weigh on Global Econ Outlook -- Market Talk

2025. g. 6. apr. 23:39 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 6. apr. 23:38 UTC

Iegādes, apvienošanās, pārņemšana

Challenger: Reinsurance Relationship With MS Primary Will Continue

2025. g. 6. apr. 23:38 UTC

Iegādes, apvienošanās, pārņemšana

Challenger: Acquisition at 53% Premium to Most Recent Share Price

2025. g. 6. apr. 23:37 UTC

Iegādes, apvienošanās, pārņemšana

Challenger: Acquisition Subject to Regulatory Approvals

2025. g. 6. apr. 23:36 UTC

Iegādes, apvienošanās, pārņemšana

Challenger: Dai-ichi Life Acquiring Stake From MS&AD Insurance

2025. g. 6. apr. 23:36 UTC

Iegādes, apvienošanās, pārņemšana

Challenger: Dai-ichi Life Paying About A$8.46/Share

2025. g. 6. apr. 23:35 UTC

Iegādes, apvienošanās, pārņemšana

Challenger: Dai-ichi Life Agrees to Acquire 15.1% Interest

2025. g. 6. apr. 21:58 UTC

Top Ziņas

Bitcoin Is Falling Amid Global Market Swoon -- Barrons.com

2025. g. 6. apr. 13:00 UTC

Top Ziņas

Trump Promised to Lower Energy Prices -- But It Wasn't Supposed to Be Like This -- WSJ

2025. g. 5. apr. 15:45 UTC

Top Ziņas

Republicans Advance Trump's Tax Cuts After Late-Night Session -- Update

2025. g. 5. apr. 15:00 UTC

Top Ziņas

U.S.-Stock Funds Have a Quarter to Forget -- Journal Report

2025. g. 5. apr. 15:00 UTC

Top Ziņas

The Complicated Relationship Between Consumer Sentiment and Stocks -- Journal Report

2025. g. 5. apr. 14:38 UTC

Top Ziņas

Trump's Trade Broadside Puts Chinese Economy Under Heavy Pressure -- WSJ

2025. g. 5. apr. 06:44 UTC

Top Ziņas

Republicans Advance Trump's Tax Cuts After Late-Night Session -- WSJ

2025. g. 5. apr. 01:00 UTC

Iegādes, apvienošanās, pārņemšana

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

2025. g. 5. apr. 01:00 UTC

Iegādes, apvienošanās, pārņemšana

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

2025. g. 4. apr. 21:53 UTC

Tirgus saruna

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

2025. g. 4. apr. 21:44 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

Salīdzinājums

Cenas izmaiņa

Emergent BioSolutions Inc Prognoze

Cenas mērķis

By TipRanks

231.86% augšup

Prognoze 12 mēnešiem

Vidējais 15 USD  231.86%

Augstākais 15 USD

Zemākais 15 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Emergent BioSolutions Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 5.1664Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

133 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.